Amgen Inc stock (US0311621009): Nasdaq shares hold near 337 USD as investors weigh Q1 2026 results and R&D spending

Amgen stock on Nasdaq is trading broadly unchanged around the mid-330 USD range as of late May 2026, with investors in the United States digesting the biotech group’s Q1 2026 earnings and its latest 125 million USD commitment to small-molecule research facilities.

Amgen stock on the Nasdaq in the United States has been changing hands in a relatively narrow corridor around the mid-330 USD area, with the shares closing at about USD 336.79 on 05/29/2026 according to MarketBeat data as of 05/31/2026, underscoring a period of consolidation after the company’s Q1 2026 earnings release and fresh research investment plans. According to MarketBeat, the consensus 12-month price target from 31 Wall Street analysts stands at USD 355.19, implying modest upside from the latest close while the consensus rating remains at hold as of late May 2026.

The stock traded at USD 336.79 on 05/29/2026 on Nasdaq, according to MarketBeat as of 05/31/2026, placing the United States-based biotech near the midpoint of its roughly USD 268 to USD 391 52-week span that has framed trading over the past year. While detailed intraday performance for 06/01/2026 has yet to be reported at the time of writing, the recent closing data suggest that Amgen’s market value around USD 187 billion as of 03/20/2026 has been relatively stable, based on figures from Stock Analysis released on that date.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: AMGN
• Sector/industry: Biotechnology, human therapeutics
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Biologic and small-molecule therapies for oncology, inflammation and other serious diseases
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc: core business model

Amgen focuses on discovering, developing, manufacturing and commercializing innovative human therapeutics, with revenue primarily generated by a portfolio of biologic and small-molecule medicines across oncology, inflammation and other serious disease areas.

What banks and research houses say about Amgen Inc

Analyst coverage for Amgen is broad across major United States and global investment banks, and aggregated data from MarketBeat as of 05/31/2026 highlight how these institutions currently view the Nasdaq-listed biotech. According to MarketBeat on that date, the consensus across 31 Wall Street equities research analysts is a hold rating on Amgen shares, with an average 12-month price target of USD 355.19, a high target of USD 427.00 and a low target of USD 200.00, which together indicate a forecasted upside of roughly 5.5 percent from the closing price of USD 336.79 on 05/29/2026.

This consensus snapshot, which reflects input from a wide range of research houses covering large-cap United States healthcare names, suggests that the market currently expects moderate share price appreciation while remaining cautious after the company’s recent earnings cycle and substantial capital allocation toward research and development infrastructure. For investors following the S&P 500 and major Nasdaq biotechnology constituents, the hold recommendation and clustered price targets around the mid-300 USD level provide context for positioning Amgen relative to other large biopharma stocks as of late May 2026.

Conclusion

Amgen shares on Nasdaq are currently trading in a relatively steady fashion around USD 336.79 as of 05/29/2026, leaving the stock mid-range within its 52-week band while the United States market digests Q1 2026 performance and ongoing investments in research capacity. The analyst consensus compiled by MarketBeat as of 05/31/2026 points to a hold stance with an average price target in the mid-350 USD area, indicating expectations of moderate upside but little near-term catalyst for a major rerating. How the company translates its research and development commitments and recent earnings trajectory into sustained revenue and profit growth will likely shape both future analyst views and investor sentiment toward the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.